Patient Oriented Research in Pediatric Kidney Disease

描述（由申请人提供）：Susan Furth，医学博士，博士是儿科学和流行病学的教授，申请更新以患者为导向的研究（K24）的职业中期奖。弗思博士有着出色的指导和成就记录。在该奖项的前4年，Furth博士成功地指导了医学生，研究员和初级教师;其中6人获得了NIH K23，KL 2或K 08职业发展奖，以及4个基金会或试点补助金，所有人都在学术界，政府或基金会进行研究。她继续与NIH/NIDDK的儿童慢性肾病队列研究（CKiD）合作并领导该研究，该研究是自2003年以来资助的一项针对美国和加拿大CKD儿童的586人队列研究。Furth博士将继续为博士后学员和初级临床研究人员提供指导活动，大多数人还将在宾夕法尼亚大学临床流行病学硕士课程中接受正式的研究培训。Furth博士预计每年为2至3名博士后研究员担任初级教师导师，并为在CKiD进行辅助研究的初级教师提供指导。她以患者为导向的研究活动将继续解决CKD的问题，重点是个人依赖透析或移植之前的疾病时期。CKiD已经达到了最初的招生目标，现在正在重新开放招生，并计划在2013年进行5年的续约申请。Furth博士将通过CKiD和她在PediGFR研究中的作用为她的学员提供研究机会，PediGFR研究是一项资助的CKiD辅助R 01，其中包括CKiD研究中1482名CKD儿童的基因分型，以及欧洲ESCAPE和4C研究。CKiD和辅助的PediGFR研究提供了一个理想的平台，可以在此基础上进行CKD病因、进展和相关合并症的遗传贡献研究。这项K24申请的其他研究目的是解决CKD中贫血和治疗抵抗的重要问题的遗传贡献。研究遗传因素对贫血易感性和治疗耐药性的影响可能会产生创新的治疗靶点。横断面和纵向分析将扩大我们对CKD贫血和治疗抵抗的遗传贡献的理解。结合现有资助研究（包括CKiD和PediGFR）的数据作为指导平台的方法将提高母研究的生产力，并推动初级研究人员的职业生涯成为肾脏疾病研究的下一代领导者。

DESCRIPTION (provided by applicant): Susan Furth, M.D., Ph.D. is a Professor of Pediatrics and Epidemiology applying to renew a Mid-career Award in Patient Oriented Research (K24). Dr. Furth has an outstanding record of mentorship and accomplishment. During the first 4 years of this award, Dr. Furth successfully mentored medical students, fellows and junior faculty; 6 of whom have received NIH K23, KL2 or K08 career development awards, and 4 foundation or pilot grant awards, all are pursuing research in academia, government or foundations. She continues to work with and lead the NIH/NIDDK's Chronic Kidney Disease in Children Cohort (CKiD) Study, a 586-person cohort study of children with CKD in the US and Canada funded since 2003. For this renewal application, Dr. Furth will continue her mentoring activities for both post-doctoral trainees and junior clinician researchers, the majority also receive formal research training in the Masters of Science Program in Clinical Epidemiology at the University of Pennsylvania.. Dr. Furth anticipates being the primary faculty mentor for 2 to 3 post-doctoral fellow mentees per year, and providing mentorship for junior faculty pursuing ancillary studies in CKiD. Her patient oriented research activities will continue to address problems in CKD, focusing on the period of disease before individuals become dependent on dialysis or transplantation. CKiD has met its initial enrollment goals and is now re-opening enrollment, and planning for a 5 year renewal application in 2013. In this K24 renewal, Dr. Furth will extend the research opportunities for her mentees through CKiD and her role on the PediGFR study, a funded ancillary R01 to CKiD which will include genotyping of a cohort of 1482 children with CKD in the CKiD study, as well as in the European ESCAPE and 4C studies. CKiD, and the ancillary PediGFR study, provide an ideal platform on which to conduct the study of genetic contributions to CKD causes, progression and associated comorbidities. The additional research aims of this K24 application address the genetic contributions to the significant problem of anemia and treatment resistance in CKD. Investigating genetic contributions to anemia susceptibility and treatment resistance may yield innovative therapeutic targets. Cross- sectional and longitudinal analyses will expand our understanding of the genetic contributions to anemia and treatment resistance in CKD. The approach of combining data from existing funded studies including CKiD and PediGFR as a platform for mentorship will increase the productivity of the parent studies and propel the careers of junior investigators to become the next generation of leaders in kidney disease research.